Financial Comparison: Ultragenyx Pharmaceutical (NASDAQ:RARE) versus Pacira BioSciences (NASDAQ:PCRX)

Pacira BioSciences (NASDAQ:PCRX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Pacira BioSciences and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1	2	3	0	2.33
Ultragenyx Pharmaceutical	1	1	16	0	2.83

Pacira BioSciences presently has a consensus price target of $30.75, suggesting a potential upside of 50.00%. Ultragenyx Pharmaceutical has a consensus price target of $72.29, suggesting a potential upside of 197.38%. Given Ultragenyx Pharmaceutical’s stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Pacira BioSciences.

Valuation and Earnings

This table compares Pacira BioSciences and Ultragenyx Pharmaceutical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$700.97 million	1.26	-$99.56 million	$0.45	45.56
Ultragenyx Pharmaceutical	$560.23 million	4.19	-$569.18 million	($5.94)	-4.09

Pacira BioSciences has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Pacira BioSciences has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.

Insider & Institutional Ownership

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Pacira BioSciences and Ultragenyx Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	2.99%	12.82%	6.57%
Ultragenyx Pharmaceutical	-91.95%	-414.17%	-43.66%

Summary

Pacira BioSciences beats Ultragenyx Pharmaceutical on 10 of the 14 factors compared between the two stocks.

About Pacira BioSciences

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.